Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours

NCT05363605 is registered in ClinicalTrials.gov with Fusion Pharmaceuticals Inc. as lead sponsor.

NCT NCT05363605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05363605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours
Lead sponsor
Fusion Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
April 20, 2022
Completion date
September 8, 2023
Enrollment
6 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, bladder carcinoma, breast cancer, colorectal cancer, fgfr3, fgfr3 overexpression, fgfr3 protein overexpression, fgfr3 receptor, gastric cancer, head and neck squamous cell carcinoma, liver cancer, lung cancer, ovarian cancer, susceptible fgfr3 genetic alterations